Pulmonary Arterial Hypertension Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, Therapies and Key Companies involved by DelveInsight | Ribomic, Gmax Biopharm, Novartis, Cereno

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Pulmonary Arterial Hypertension pipeline constitutes 55+ key companies continuously working towards developing 55+ Pulmonary Arterial Hypertension treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Pulmonary Arterial Hypertension Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pulmonary Arterial Hypertension Market.

The Pulmonary Arterial Hypertension Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Pulmonary Arterial Hypertension Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Pulmonary Arterial Hypertension treatment therapies with a considerable amount of success over the years.

*
Pulmonary Arterial Hypertension companies working in the treatment market are Centessa Pharmaceuticals, Ribomic, Gmax Biopharm LLC., Novartis Pharmaceuticals, Cereno Scientific AB, Insmed Incorporated, Aerovate Therapeutics, Pharmosa Biopharm Inc, and others, are developing therapies for the Pulmonary Arterial Hypertension treatment

*
Emerging Pulmonary Arterial Hypertension therapies in the different phases of clinical trials are- MGX292, RBM-011, GMA301, LTP001, CS1, Treprostinil Palmitil, AV-101, L606, and others are expected to have a significant impact on the Pulmonary Arterial Hypertension market in the coming years.

*
In October 2024, Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical firm focused on developing protein kinase inhibitor therapies to alter the progression of cardiopulmonary and neurodegenerative diseases through Abelson Tyrosine Kinase inhibition, has announced the successful completion of a private placement raising approximately $110 million from the issuance and sale of shares of the Company's common stock along with accompanying warrants. This private placement has the potential to provide total financing of up to around $275 million upon the full cash exercise of the issued warrants, before accounting for placement agent fees and offering expenses. The funds will be used to support the Phase 2b '702' trial in Pulmonary Arterial Hypertension (PAH) and for general corporate purposes.

*
In September 2024, Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for various disorders associated with dysfunctional signaling of the transforming growth factor-beta ("TGF-Ss") protein family, has announced the completion of screening for the TROPOS trial. This Phase 2 clinical trial evaluates cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"). Consequently, Keros anticipates finishing enrollment by the end of September and plans to present topline data in the second quarter of 2025.

*
In March 2024, Merck (NYSE: MRK), also known as MSD outside the United States and Canada, has announced today that the U.S. Food and Drug Administration (FDA) has given approval for sotatercept-csrk (U.S. Brand Name: WINREVAIR Trademark , for injection, 45mg, 60mg) for the management of pulmonary arterial hypertension (PAH) in adults. This medication is indicated to enhance exercise capacity, ameliorate World Health Organization (WHO) functional class (FC), and mitigate the risk of clinical worsening events. WINREVAIR had previously received Breakthrough Therapy Designation from the FDA. It represents the first FDA-approved therapy targeting activin signaling inhibition for PAH, offering a novel therapeutic approach by modulating the balance between pro- and anti-proliferative signaling to regulate vascular cell proliferation associated with PAH.

*
In January 2024, Pulnovo Medical Limited, a globally renowned innovator in medical devices for treating Pulmonary Hypertension (PH) and Heart Failure (HF), has recently achieved Humanitarian Use Device (HUD) designation from the US FDA and approval from China's National Medical Products Administration (NMPA) for the PADN Catheter and Generator. The PADN technology marks a significant breakthrough in the realm of global interventional pulmonary arterial hypertension (PAH), addressing challenges in PAH interventional therapy

Pulmonary Arterial Hypertension Overview

Pulmonary Arterial Hypertension (PAH) is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It occurs when the small arteries in the lungs become narrowed, blocked, or destroyed, which increases resistance in the blood flow. As a result, the heart has to work harder to pump blood through the lungs, which can weaken the heart over time and potentially lead to heart failure. Symptoms of PAH include shortness of breath, fatigue, chest pain, and swelling in the ankles or legs. Treatments focus on managing symptoms and improving quality of life, though there is currently no cure for PAH.

Get a Free Sample PDF Report to know more about Pulmonary Arterial Hypertension Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-pipeline-insight [https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Pulmonary Arterial Hypertension Drugs Under Different Phases of Clinical Development Include:

*
MGX292: Centessa Pharmaceuticals

*
RBM-011: Ribomic

*
GMA301: Gmax Biopharm LLC.

*
LTP001 : Novartis Pharmaceuticals

*
CS1: Cereno Scientific AB

*
Treprostinil Palmitil: Insmed Incorporated

*
AV-101: Aerovate Therapeutics

*
L606: Pharmosa Biopharm Inc

Pulmonary Arterial Hypertension Route of Administration

Pulmonary Arterial Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravitreal

*
Subretinal

*
Topical

*
Molecule Type

Pulmonary Arterial Hypertension Molecule Type

Pulmonary Arterial Hypertension Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

*
Product Type

Pulmonary Arterial Hypertension Pipeline Therapeutics Assessment

*
Pulmonary Arterial Hypertension Assessment by Product Type

*
Pulmonary Arterial Hypertension By Stage and Product Type

*
Pulmonary Arterial Hypertension Assessment by Route of Administration

*
Pulmonary Arterial Hypertension By Stage and Route of Administration

*
Pulmonary Arterial Hypertension Assessment by Molecule Type

*
Pulmonary Arterial Hypertension by Stage and Molecule Type

DelveInsight's Pulmonary Arterial Hypertension Report covers around 55+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Pulmonary Arterial Hypertension product details are provided in the report. Download the Pulmonary Arterial Hypertension pipeline report to learn more about the emerging Pulmonary Arterial Hypertension therapies [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Pulmonary Arterial Hypertension Therapeutics Market include:

Key companies developing therapies for Pulmonary Arterial Hypertension are - VasThera Co Ltd, Altavant Sciences Inc, Alterras Therapeutics GmbH, United Therapeutics Corp, Chiesi Farmaceutici SpA, Gmax Biopharm LLC, Antlia Bioscience Inc, and others.

Pulmonary Arterial Hypertension Pipeline Analysis:

The Pulmonary Arterial Hypertension pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Pulmonary Arterial Hypertension with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Arterial Hypertension Treatment.

*
Pulmonary Arterial Hypertension key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Pulmonary Arterial Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pulmonary Arterial Hypertension market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Pulmonary Arterial Hypertension drugs and therapies [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Pulmonary Arterial Hypertension Pipeline Market Drivers

*
Rising prevalence of Pulmonary Arterial Hypertension worldwide, robust Drug pipeline and the new product combinations are some of the important factors that are fueling the Pulmonary Arterial Hypertension Market.

Pulmonary Arterial Hypertension Pipeline Market Barriers

*
However, high cost associated with the treatment of Pulmonary Arterial Hypertension, lack of awareness among people in developing countries and other factors are creating obstacles in the Pulmonary Arterial Hypertension Market growth.

Scope of Pulmonary Arterial Hypertension Pipeline Drug Insight

*
Coverage: Global

*
Key Pulmonary Arterial Hypertension Companies: Centessa Pharmaceuticals, Ribomic, Gmax Biopharm LLC., Novartis Pharmaceuticals, Cereno Scientific AB, Insmed Incorporated, Aerovate Therapeutics, Pharmosa Biopharm Inc, and others

*
Key Pulmonary Arterial Hypertension Therapies: MGX292, RBM-011, GMA301, LTP001, CS1, Treprostinil Palmitil, AV-101, L606, and others

*
Pulmonary Arterial Hypertension Therapeutic Assessment: Pulmonary Arterial Hypertension current marketed and Pulmonary Arterial Hypertension emerging therapies

*
Pulmonary Arterial Hypertension Market Dynamics: Pulmonary Arterial Hypertension market drivers and Pulmonary Arterial Hypertension market barriers

Request for Sample PDF Report for Pulmonary Arterial Hypertension Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Pulmonary Arterial Hypertension Report Introduction

2. Pulmonary Arterial Hypertension Executive Summary

3. Pulmonary Arterial Hypertension Overview

4. Pulmonary Arterial Hypertension- Analytical Perspective In-depth Commercial Assessment

5. Pulmonary Arterial Hypertension Pipeline Therapeutics

6. Pulmonary Arterial Hypertension Late Stage Products (Phase II/III)

7. Pulmonary Arterial Hypertension Mid Stage Products (Phase II)

8. Pulmonary Arterial Hypertension Early Stage Products (Phase I)

9. Pulmonary Arterial Hypertension Preclinical Stage Products

10. Pulmonary Arterial Hypertension Therapeutics Assessment

11. Pulmonary Arterial Hypertension Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Pulmonary Arterial Hypertension Key Companies

14. Pulmonary Arterial Hypertension Key Products

15. Pulmonary Arterial Hypertension Unmet Needs

16 . Pulmonary Arterial Hypertension Market Drivers and Barriers

17. Pulmonary Arterial Hypertension Future Perspectives and Conclusion

18. Pulmonary Arterial Hypertension Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pulmonary-arterial-hypertension-pipeline-update-2024-fda-approvals-therapeutic-advancements-therapies-and-key-companies-involved-by-delveinsight-ribomic-gmax-biopharm-novartis-cereno]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.